On ECHEMI
Home > Drugs > INNER MONGOLIA BAIYI Pharmaceutical Co., Ltd.
INNER MONGOLIA BAIYI Pharmaceutical Co., Ltd.
  • Founded in:

    2003-11-12
  • Country:

    China China
  • Address:

    No. 5, Central Road, Ulanhot Economic and Technological Development Zone, Inner Mongolia Autonomous Region
  • Tax NO.:

    91150000701336455A
  • Registered Funds:

    140 million yuan
  • Email:

Related Drugs
Diammonium Glycyrrhizinate for Injection
The main ingredient of this product is diammonium glycyrrhizinate. Its chemical name is: 20β-carboxyl-11-oxo-n-oleanol-12-ene-3β-yl-2-O-β-D-glucopyranosiduronic acid-a-D-glucopyranosiduronic acid diammonium salt.
Name Description Content CAS NO. Registered Holders
Diammonium glycyrrhizinate

This product has strong anti-inflammatory, liver cell membrane protection and liver function improvement effects. Pharmacological experiments have shown that oral administration of this product to mice can reduce the increase of serum alanine aminotransferase and aspartate aminotransferase caused by carbon tetrachloride, thioacetamide and D-galactosamine. It can also significantly reduce the morphological damage of D-galactosamine to the liver and improve the chronic damage of immune factors to the liver morphology.

More

This product has strong anti-inflammatory, liver cell membrane protection and liver function improvement effects. Pharmacological experiments have shown that oral administration of this product to mice can reduce the increase of serum alanine aminotransferase and aspartate aminotransferase caused by carbon tetrachloride, thioacetamide and D-galactosamine. It can also significantly reduce the morphological damage of D-galactosamine to the liver and improve the chronic damage of immune factors to the liver morphology.

79165-06-3 35
Propyl Gallate for Injection
The main ingredient of this product is propyl gallate
Name Description Content CAS NO. Registered Holders
Propyl gallate

1. It can obviously inhibit the synthesis of thromboxane A2 (TXA2), counteract the platelet aggregation caused by arachidonic acid (AA), and has a stronger and faster antiplatelet aggregation effect than aspirin (ASP). 2. It can enhance the fibrinolytic activity and promote the dissolution of thrombus. 3. It can reduce the specific viscosity of whole blood and plasma, and accelerate the electrophoresis of red blood cells. 4. It can relax the vascular smooth muscle, dilate the artery, and increase the blood flow of the coronary artery and cerebral artery. 5. It can improve the ability to resist hypoxia. 6. It can strongly scavenge free radicals. 7. It can inhibit the inflammatory exudation of capillaries.

More

1. It can obviously inhibit the synthesis of thromboxane A2 (TXA2), counteract the platelet aggregation caused by arachidonic acid (AA), and has a stronger and faster antiplatelet aggregation effect than aspirin (ASP). 2. It can enhance the fibrinolytic activity and promote the dissolution of thrombus. 3. It can reduce the specific viscosity of whole blood and plasma, and accelerate the electrophoresis of red blood cells. 4. It can relax the vascular smooth muscle, dilate the artery, and increase the blood flow of the coronary artery and cerebral artery. 5. It can improve the ability to resist hypoxia. 6. It can strongly scavenge free radicals. 7. It can inhibit the inflammatory exudation of capillaries.

121-79-9 10
Piracetam for injection
Name Description Content CAS NO. Registered Holders
Piracetam

Extract from the above information

More

Extract from the above information

7491-74-9 24
Pentoxifylline for injection
3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione
Name Description Content CAS NO. Registered Holders
(+/-)-Verapamil hydrochloride

1. Calcium ion antagonist, regulates calcium ion influx on the membrane of myocardial conduction cells, myocardial contractile cells and arterial smooth muscle cells, without changing serum calcium concentration; 2. Dilates the main coronary arteries and arterioles, antagonizes coronary artery spasm, increases myocardial oxygen delivery, reduces peripheral resistance, and reduces myocardial oxygen consumption; 3. Prolongs the effective refractory period of the atrioventricular node, slows conduction, and reduces the ventricular rate of patients with chronic atrial fibrillation and atrial flutter; 4. Reduces systemic vascular resistance to produce a hypotensive effect, generally without causing postural hypotension or reflex tachycardia; 5. Reduces afterload, inhibits myocardial contraction, and improves left ventricular diastolic function; 6. Animal experiments show that the local anesthetic effect is 1.6 times that of procaine equimolar.

More

1. Calcium ion antagonist, regulates calcium ion influx on the membrane of myocardial conduction cells, myocardial contractile cells and arterial smooth muscle cells, without changing serum calcium concentration; 2. Dilates the main coronary arteries and arterioles, antagonizes coronary artery spasm, increases myocardial oxygen delivery, reduces peripheral resistance, and reduces myocardial oxygen consumption; 3. Prolongs the effective refractory period of the atrioventricular node, slows conduction, and reduces the ventricular rate of patients with chronic atrial fibrillation and atrial flutter; 4. Reduces systemic vascular resistance to produce a hypotensive effect, generally without causing postural hypotension or reflex tachycardia; 5. Reduces afterload, inhibits myocardial contraction, and improves left ventricular diastolic function; 6. Animal experiments show that the local anesthetic effect is 1.6 times that of procaine equimolar.

152-11-4 13
Potassium Aspartate Injection
Name Description Content CAS NO. Registered Holders
Potassium L-aspartate

14007-45-5 11
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.